Table of Contents Author Guidelines Submit a Manuscript
Corrigendum

A corrigendum for this article has been published. To view the corrigendum, please click here.

Evidence-Based Complementary and Alternative Medicine
Volume 2016, Article ID 7620817, 13 pages
http://dx.doi.org/10.1155/2016/7620817
Research Article

Effect of Glycyrrhiza on the Diuretic Function of Euphorbia kansui: An Ascites Mouse Model

1College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China
2Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China
3Jiangsu Provincial Key Laboratory for Formulae Research, Nanjing University of Traditional Chinese Medicine, Nanjing 210046, China
4Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing 100102, China

Received 6 January 2016; Revised 25 March 2016; Accepted 6 April 2016

Academic Editor: Alfredo Vannacci

Copyright © 2016 Ya Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F.-R. Yu, X.-Z. Lian, H.-Y. Guo et al., “Isolation and characterization of methyl esters and derivatives from Euphorbia kansui (Euphorbiaceae) and their inhibitory effects on the human SGC-7901 cells,” Journal of Pharmacy & Pharmaceutical Sciences, vol. 8, no. 3, pp. 528–535, 2005. View at Google Scholar · View at Scopus
  2. L. Chen, “In vitro experimental study of the effect of Euphorbia kansui extract on human BEL-7402,” Acta Botanica Boreali Occidentalia Sinica, vol. 28, no. 9, pp. 1889–1892, 2008. View at Google Scholar
  3. F. Yu, S. Lu, F. Yu, J. Shi, P. M. McGuire, and R. Wang, “Cytotoxic activity of an octadecenoic acid extract from Euphorbia kansui (Euphorbiaceae) on human tumour cell strains,” The Journal of Pharmacy and Pharmacology, vol. 60, no. 2, pp. 253–259, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. X. Wang, H. Zhang, L. Chen, L. Shan, G. Fan, and X. Gao, “Liquorice, a unique ‘guide drug’ of traditional Chinese medicine: a review of its role in drug interactions,” Journal of Ethnopharmacology, vol. 150, no. 3, pp. 781–790, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Wang and H. Li, “Application of GSBXT in treatment of fluid retention,” Journal of Handan Medical College, vol. 10, pp. 182–183, 1997. View at Google Scholar
  6. C. Hao, Y. Shi, J. Yu, X. Wei, S. Li, and Z. Tong, “The therapeutic function of the chemokine RANTES on the H22 hepatoma ascites model,” Molecular and Cellular Biochemistry, vol. 367, no. 1-2, pp. 93–102, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Fang, Uniform Design and Uniform Design Table, Science Press, Beijing, China, 1994.
  8. K. Fang, “Uniform design and its application,” Journal of Applied Statistics and Management, vol. 13, no. 4, pp. 56–63, 1994. View at Google Scholar
  9. X. Sun, Y. Wu, and Q. Xu, “Uniform design and its application in the pharmaceutical field,” Anhui Medical and Pharmaceutical Journal, vol. 13, no. 7, pp. 822–824, 2009. View at Google Scholar
  10. H. Zhou, P. Long, and S. Lin, “Uniform design and its application in pharmaceutical research in design,” Journal of Mathematical Medicine, vol. 10, no. 3, pp. 251–253, 1997. View at Google Scholar
  11. L. Ma, J.-G. Liu, and D.-Z. Shi, “Application of uniform design in research of traditional Chinese medicine,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 25, no. 3, pp. 278–281, 2005. View at Google Scholar · View at Scopus
  12. S.-S. Kong, J.-J. Liu, T.-C. Hwang et al., “Optimizing the parameters of vagus nerve stimulation by uniform design in rats with acute myocardial infarction,” PLoS ONE, vol. 7, no. 11, Article ID e42799, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. R. C. Gonzalez and E. Richard, Woods's Digital Image Processing (Matlab Version), Publishing House of Electronics Industry, Beijing, China, 2001.
  14. W. Sha, W. Tan, Y. Shen et al., “CGMS data-integration software based on MATLAB analysis and its use in diabetic patients with hypoglycemia,” Chinese Journal of Medical Physics, vol. 31, no. 3, pp. 4936–4940, 2014. View at Google Scholar
  15. National Pharmacopoeia Committee, Pharmacopoeiao People's Republic of China (Part I), vol. I, Chnical Industry Press, Beijing, China, 2010.
  16. F. Zhu, Z. Shi, C. Qin et al., “Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery,” Nucleic Acids Research, vol. 40, no. 1, pp. D1128–D1136, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. Z. Zsoldos, D. Reid, A. Simon, B. S. Sadjad, and A. P. Johnson, “eHiTS: an innovative approach to the docking and scoring function problems,” Current Protein & Peptide Science, vol. 7, no. 5, pp. 421–435, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. T. D. Cushing, X. Hao, Y. Shin et al., “Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kδ inhibitors for inflammation and autoimmune disease,” Journal of Medicinal Chemistry, vol. 58, no. 1, pp. 480–511, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Zhang, X. Wang, and H. Lu, “Amifostine increases cure rate of cisplatin on ascites hepatoma 22 via selectively protecting renal thioredoxin reductase,” Cancer Letters, vol. 260, no. 1-2, pp. 127–136, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. V. Gamblin, A. Da Silva, S. Villet, and F. El Hajbi, “Prise en charge symptomatique de l'ascite maligne en phase palliative : place de la paracentèse et des diurétiques,” Bulletin du Cancer, vol. 102, no. 11, pp. 940–945, 2015. View at Publisher · View at Google Scholar
  21. J. S. Spratt, M. Edwards, T. Kubota, R. Lindberg, and M. T. Tseng, “Peritoneal carcinomatosis: anatomy, physiology, diagnosis, management,” Current Problems in Cancer, vol. 10, no. 11, pp. 553–584, 1986. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Chung and P. Kozuch, “Treatment of malignant ascites,” Current Treatment Options in Oncology, vol. 9, no. 2-3, pp. 215–233, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Zhou, F. Wen, P. Zhang, R. Tang, and Q. Li, “Matrix protein of vesicular stomatitis virus: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation,” Cancer Gene Therapy, vol. 20, no. 3, pp. 178–185, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Zhang, D. Qian, Y. Pan et al., “Comparisons of the pharmacokinetic profile of four bioactive components after oral administration of gan-sui-ban-xia decoction plus-minus gansui and gancao drug combination in normal rats,” Molecules, vol. 20, no. 5, pp. 9295–9308, 2015. View at Publisher · View at Google Scholar
  25. Z.-Y. Jiang, S.-K. Qin, X.-J. Yin, Y.-L. Chen, and L. Zhu, “Synergistic effects of Endostar combined with β-elemene on malignant ascites in a mouse model,” Experimental and Therapeutic Medicine, vol. 4, no. 2, pp. 277–284, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. X.-M. Li, Y.-Y. Hu, and X.-H. Duan, “Uniform designed research on the active ingredients assembling of Chinese medicine prescription for anti-liver fibrosis,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 30, no. 1, pp. 58–63, 2010 (Chinese). View at Google Scholar · View at Scopus
  27. R. A. Fenton, “Essential role of vasopressin-regulated urea transport processes in the mammalian kidney,” Pflügers Archiv, vol. 458, no. 1, pp. 169–177, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. http://www.genecards.org/cgi-bin/carddisp.pl?gene=AVPR2.
  29. J. H. Robben, N. V. A. M. Knoers, and P. M. T. Deen, “Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus,” American Journal of Physiology—Renal Physiology, vol. 291, no. 2, pp. F257–F270, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. I. Sakaida, “Tolvaptan for the treatment of liver cirrhosis oedema,” Expert Review of Gastroenterology and Hepatology, vol. 8, no. 5, pp. 461–470, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Watson, P. Jepsen, F. Wong, P. Ginès, J. Córdoba, and H. Vilstrup, “Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development,” Metabolic Brain Disease, vol. 28, no. 2, pp. 301–305, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Habib and T. D. Boyer, “Vasopressin V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia,” Therapeutic Advances in Gastroenterology, vol. 5, no. 3, pp. 189–197, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. H. B. Moeller, S. Rittig, and R. A. Fenton, “Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment,” Endocrine Reviews, vol. 34, no. 2, pp. 278–301, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Nielsen, J. Frøkiær, D. Marples, T.-H. Kwon, P. Agre, and M. A. Knepper, “Aquaporins in the kidney: from molecules to medicine,” Physiological Reviews, vol. 82, no. 1, pp. 205–244, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. S.-S. Moon, H.-J. Kim, Y.-K. Choi et al., “Novel mutation of aquaporin-2 gene in a patient with congenital nephrogenic diabetes insipidus,” Endocrine Journal, vol. 56, no. 7, pp. 905–910, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. D. G. Bichet, A. El Tarazi, J. Matar et al., “Aquaporin-2: new mutations responsible for autosomal-recessive nephrogenic diabetes insipidus—update and epidemiology,” Clinical Kidney Journal, vol. 5, no. 3, pp. 195–202, 2012. View at Publisher · View at Google Scholar · View at Scopus